Endologix, Inc. (NASDAQ:ELGX) Expected to Post Earnings of -$0.80 Per Share

Wall Street brokerages expect that Endologix, Inc. (NASDAQ:ELGX) will report earnings of ($0.80) per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Endologix’s earnings. The highest EPS estimate is ($0.59) and the lowest is ($0.95). Endologix posted earnings per share of ($1.80) during the same quarter last year, which would suggest a positive year over year growth rate of 55.6%. The company is expected to issue its next quarterly earnings report on Thursday, August 8th.

According to Zacks, analysts expect that Endologix will report full-year earnings of ($3.65) per share for the current fiscal year, with EPS estimates ranging from ($5.77) to ($2.60). For the next year, analysts expect that the firm will post earnings of ($2.68) per share, with EPS estimates ranging from ($4.36) to ($1.37). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Endologix.

Endologix (NASDAQ:ELGX) last issued its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported ($1.12) earnings per share for the quarter, beating the consensus estimate of ($1.56) by $0.44. The company had revenue of $35.61 million during the quarter, compared to analysts’ expectations of $34.18 million. Endologix had a negative return on equity of 173.52% and a negative net margin of 54.72%.

Several brokerages have recently weighed in on ELGX. Zacks Investment Research cut Endologix from a “hold” rating to a “sell” rating in a research note on Monday, March 11th. BTIG Research reissued a “buy” rating on shares of Endologix in a research note on Tuesday, February 26th. Stifel Nicolaus set a $7.00 price target on Endologix and gave the company a “hold” rating in a research note on Monday, April 1st. Finally, ValuEngine cut Endologix from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the stock. Endologix currently has a consensus rating of “Hold” and an average price target of $25.63.

In other Endologix news, CEO John Onopchenko bought 30,257 shares of the business’s stock in a transaction that occurred on Wednesday, April 3rd. The shares were bought at an average price of $6.61 per share, for a total transaction of $199,998.77. Following the transaction, the chief executive officer now directly owns 96,360 shares in the company, valued at $636,939.60. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Vaseem Mahboob bought 15,128 shares of the business’s stock in a transaction that occurred on Wednesday, April 3rd. The shares were acquired at an average price of $6.61 per share, for a total transaction of $99,996.08. Following the transaction, the chief financial officer now owns 76,820 shares in the company, valued at $507,780.20. The disclosure for this purchase can be found here. In the last three months, insiders bought 48,410 shares of company stock valued at $319,990. Insiders own 1.40% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its position in shares of Endologix by 8.9% during the 4th quarter. BlackRock Inc. now owns 6,208,597 shares of the medical instruments supplier’s stock valued at $4,446,000 after purchasing an additional 509,493 shares in the last quarter. Stephens Inc. AR boosted its position in shares of Endologix by 25.0% during the 4th quarter. Stephens Inc. AR now owns 2,398,414 shares of the medical instruments supplier’s stock valued at $1,717,000 after purchasing an additional 480,074 shares in the last quarter. D. E. Shaw & Co. Inc. boosted its position in shares of Endologix by 17.3% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,941,830 shares of the medical instruments supplier’s stock valued at $1,390,000 after purchasing an additional 286,366 shares in the last quarter. Mackenzie Financial Corp boosted its position in shares of Endologix by 7.9% during the 4th quarter. Mackenzie Financial Corp now owns 1,832,148 shares of the medical instruments supplier’s stock valued at $1,312,000 after purchasing an additional 134,149 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of Endologix by 15.9% during the 4th quarter. Northern Trust Corp now owns 1,215,671 shares of the medical instruments supplier’s stock valued at $871,000 after purchasing an additional 166,409 shares in the last quarter. Institutional investors own 48.67% of the company’s stock.

Shares of ELGX stock opened at $7.87 on Friday. The company has a 50-day moving average of $7.10. The company has a quick ratio of 0.90, a current ratio of 1.58 and a debt-to-equity ratio of 11.12. Endologix has a 1-year low of $5.20 and a 1-year high of $59.50.

About Endologix

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.

Featured Article: Oversold

Get a free copy of the Zacks research report on Endologix (ELGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.